Supernus Pharmaceuticals Newsroom

Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $38

Futu News24minutes ago · Ratings

Analysts Offer Insights on Healthcare Companies: Supernus Pharmaceuticals (SUPN), Editas Medicine (EDIT) and Revvity (RVTY)

TipRanks50minutes ago · Ratings

Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $36

Futu News20:31 · Ratings

Piper Sandler Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)

TipRanks19:58 · Ratings

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript Summary

Futu News11:55 · Conference Call

TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43

Futu News09:31 · Ratings

Strong Q3 Performance and Promising Future for Supernus Pharmaceuticals Backed by Qelbree's Success

TipRanks09:25

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

Yahoo Finance08:35

Supernus Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

SEC05:24 · Announcements

Supernus Pharmaceuticals GAAP EPS of $0.69, Revenue of $175.69M Beats by $18.39M

Seeking Alpha05:15

Supernus Pharmaceuticals Sees FY24 Total Revenue $630M-$650M Vs $619.505M Est.

Benzinga05:11

Express News | Supernus Pharmaceuticals Q3 Adjusted Revenue USD 130.6 Million Vs. IBES Estimate USD 157.3 Million

Breakings05:05

Press Release: Supernus Announces Third Quarter 2024 Financial Results

Dow Jones05:05

Supernus Pharmaceuticals 3Q Rev $175.7M >SUPN

Dow Jones05:05

Supernus Pharmaceuticals 3Q Net $38.5M >SUPN

Dow Jones05:05

Supernus Presents Promising Data From Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

GlobeNewswireNov 1 04:10

Express News | Supernus Pharmaceuticals : Spn-820 Shows 50% Madrs Response Rate, 35% Remission Rate at 4 Hours

BreakingsOct 31 05:47

Earnings Preview: SUPN to Report Financial Results Post-market on November 04

$Supernus Pharmaceuticals(SUPN.US)$ is scheduled to release its financial results post-market on November 04 ET. Earnings PreviewAnalysts estimate $Supernus Pharmaceuticals(SUPN.US)$ to post revenue

Futu NewsOct 30 09:00

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

GlobeNewswireOct 22 04:25

A Quick Look at Today's Ratings for Supernus Pharmaceuticals(SUPN.US), With a Forecast Between $36 to $43

Futu NewsOct 18 21:00 · Ratings